[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hanyang University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100640516","phase-4-effects-of-ginkgo-biloba-on-blood-biomarkers-in-mild-cognitive-impairment-100640516",false,"NCT07579689","Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment","Effect of Gingko Biloba on the Blood Biomarkers in Mild Cognitive Impairment Patients With Alzheimer's Disease","Inclusion Criteria:\n\n* Age 20 years or older\n* Clinical Dementia Rating (CDR) score of 0.5\n* Patients clinically indicated for treatment with Ginkgo biloba extract\n\nExclusion Criteria:\n\n* Current use of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine.\n* Refusal to provide informed consent.\n* Presence of neurological or psychiatric conditions other than Alzheimer's disease that may affect cognitive function.\n* Known hypersensitivity to Ginkgo biloba extract or any of its components.\n* Pregnant women.\n* Genetic conditions associated with lactose intolerance, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Presence of bleeding disorders at screening, or requirement for continuous use of medications that may affect study drug efficacy (e.g., anticoagulants, antiplatelets, thrombolytics, peripheral vasodilators, PGE1 and its derivatives).\n* Any condition that, in the opinion of the investigator or study staff, makes the participant unsuitable for the study or unable to comply with study procedures.","ALL","20 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.",[26,27],"Mild Cognitive Impairment","Alzheimer's Disease",[26,29,27,30],"Ginexin","Ginkgo Biloba Extract","NOT_YET_RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":20},"2026-06",{"date":39,"type":20},"2028-12-31",{"name":41,"class":42},"Hanyang University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100578499","human-microbiome-research-and-development-for-overcoming-pediatric-diseases-100578499","NCT06812091","Human Microbiome Research and Development for Overcoming Pediatric Diseases","Prediction and Treatment of Pediatric Diseases and Long-term Outcomes Through Microbiome and Multi-Omics Study by Life Cycle","Inclusion Criteria:\n\n* children (including newborns) who have obtained their consent from their guardians\n\nExclusion Criteria:\n\n* subjects who did not obtain consent",true,{"count":52,"type":20},500,"10 Years","OBSERVATIONAL","Prediction and treatment of pediatric diseases and long-term outcomes through microbiome and multi-omics analysis by life cycle: We aim to demonstrate that a wide range of diseases are associated with gut microbiome dysbiosis and to investigate the subsequent recovery (restoration) or further deterioration of the gut microbiome over time. This study seeks to offer a novel perspective on changes in the gut microbiome, particularly in the context of the gut-lung and gut-brain axes.",[57,58,59,60],"Human Microbiome","Pediatrics","Disease","Growth & Development","RECRUITING","2025-02-01",{"date":64,"type":35},"2025-02-06",{"date":66,"type":35},"2022-01-01",{"date":68,"type":20},"2030-01-01",{"name":41,"class":42},1,""]